<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3AStructural_remedy</id>
	<title>Definition:Structural remedy - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3AStructural_remedy"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Structural_remedy&amp;action=history"/>
	<updated>2026-05-02T18:33:04Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Structural_remedy&amp;diff=20746&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Structural_remedy&amp;diff=20746&amp;oldid=prev"/>
		<updated>2026-03-18T03:15:55Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;📋 &amp;#039;&amp;#039;&amp;#039;Structural remedy&amp;#039;&amp;#039;&amp;#039; is a corrective measure imposed by a competition authority or [[Definition:Regulatory authority | regulator]] that permanently alters the organizational or ownership structure of firms within a market, rather than merely prescribing behavioral rules. In the insurance industry, structural remedies most commonly arise in the context of [[Definition:Mergers and acquisitions (M&amp;amp;A) | mergers and acquisitions]], where a competition authority determines that a proposed combination would substantially lessen competition and requires the merging parties to divest specific business units, [[Definition:Book of business | books of business]], or [[Definition:Distribution channel | distribution]] assets as a condition for approval. The remedy is &amp;quot;structural&amp;quot; because it changes who owns what, creating a durable market adjustment that does not require ongoing regulatory monitoring of conduct.&lt;br /&gt;
&lt;br /&gt;
⚙️ When a major insurer or [[Definition:Insurance broker | brokerage]] seeks to acquire a competitor, competition authorities — such as the European Commission, the US Department of Justice, the UK&amp;#039;s Competition and Markets Authority (CMA), or equivalent bodies in Asia — assess whether the transaction would concentrate market power to the detriment of [[Definition:Policyholder | policyholders]], cedants, or competing firms. If concerns arise, the authority may clear the deal subject to divestitures. In the brokerage sector, for example, large-scale consolidation has occasionally required the disposing of certain specialty [[Definition:Line of business | lines]], regional operations, or client portfolios to preserve competitive alternatives for buyers of [[Definition:Insurance coverage | coverage]]. In [[Definition:Reinsurance | reinsurance]], structural remedies might involve the sale of specific treaty portfolios or [[Definition:Managing general agent (MGA) | MGA]] platforms. The divested assets must typically go to an approved purchaser capable of operating them as a viable, independent competitive force — a requirement that prevents cosmetic compliance.&lt;br /&gt;
&lt;br /&gt;
📊 What distinguishes structural remedies from [[Definition:Sector inquiry | behavioral remedies]] — such as mandated pricing transparency, access commitments, or conduct undertakings — is their self-executing nature. Once a divestiture is completed, the competitive landscape is permanently reshaped without the need for years of compliance monitoring. Competition authorities generally prefer structural solutions for this reason, viewing them as cleaner and more effective than ongoing behavioral oversight. For insurance industry participants, understanding this distinction matters during strategic planning: firms contemplating transformative acquisitions should conduct pre-deal competition analysis to identify potential divestiture requirements early, factor them into valuation models, and prepare divestiture packages that will satisfy regulators while preserving the strategic rationale of the transaction. Failure to anticipate structural remedy demands can delay or derail deals, erode value, and create uncertainty for employees, clients, and [[Definition:Insurance carrier | carrier]] partners.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Mergers and acquisitions (M&amp;amp;A)]]&lt;br /&gt;
* [[Definition:Sector inquiry]]&lt;br /&gt;
* [[Definition:Competition law]]&lt;br /&gt;
* [[Definition:Market concentration]]&lt;br /&gt;
* [[Definition:Regulatory authority]]&lt;br /&gt;
* [[Definition:Divestiture]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>